Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 5/20 | 0.50 |
| ▸ | PRMT3 | O60678 | 6/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19932325 | 0.87 | IMPDH2 (0.41) | IMPDH2PRMT3NOTUMROCK2ROCK1 | |
| SCHEMBL9883175 | 0.82 | IMPDH2 (0.57) | IMPDH2PRMT3NOTUMROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL111516 | 0.81 | IMPDH2 (0.56) | IMPDH2PRMT3NOTUMROCK2ROCK1 | |
| SCHEMBL2162932 | 0.79 | PRMT3 (0.61) | IMPDH2PRMT3NOTUM | |
| SCHEMBL29183948 | 0.78 | ROCK2 (0.65) | ROCK2ROCK1 | |
| SCHEMBL21119166 | 0.75 | ROCK2 (0.55) | IMPDH2PRMT3NOTUMROCK2ROCK1 | |
| SCHEMBL1105145 | 0.74 | ROCK2 (0.60) | IMPDH2ROCK2ROCK1 | |
| SCHEMBL20353507 | 0.73 | IMPDH2 (0.63) | IMPDH2PRMT3NOTUMROCK2ROCK1 | |
| SCHEMBL3407225 | 0.73 | IMPDH2 (0.56) | IMPDH2PRMT3NOTUMROCK2ROCK1 | |
| SCHEMBL1095868 | 0.73 | IMPDH2 (0.56) | IMPDH2PRMT3NOTUMROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2021-11-25 | — | — | US | disclosed |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3828172-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3354643-B1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10654844-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200131171-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2020-04-30 | — | — | US | disclosed |
| US-10316029-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10174017-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180215749-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2018-08-02 | — | — | US | disclosed |
| US-9951059-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2424842-B1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150175549-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140187617-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8716310-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130158015-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
| WO-2010126626-A2 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187617-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
| US-10654844-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
| US-20130158015-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
| US-20200131171-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
| US-20150175549-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
| US-20180215749-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
| US-10316029-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
| US-11028081-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
| US-20210363141-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | IMPDH2 179/4885PRMT3 1989/4885NOTUM 2222/4885 |
| US-10174017-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | IMPDH2 236/4885PRMT3 1452/4885NOTUM 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.